Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) EBT (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed EBT for 6 consecutive years, with -$14.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 80.05% year-over-year to -$14.6 million, compared with a TTM value of -$76.1 million through Sep 2025, down 29.47%, and an annual FY2024 reading of -$61.2 million, up 19.99% over the prior year.
  • EBT was -$14.6 million for Q3 2025 at Barinthus Biotherapeutics, up from -$21.2 million in the prior quarter.
  • Across five years, EBT topped out at $14.8 million in Q2 2022 and bottomed at -$25.0 million in Q2 2023.
  • Average EBT over 5 years is -$12.6 million, with a median of -$16.7 million recorded in 2021.
  • The sharpest move saw EBT skyrocketed 249.21% in 2022, then tumbled 2926.4% in 2023.
  • Year by year, EBT stood at -$16.7 million in 2021, then crashed by 38.93% to -$23.2 million in 2022, then grew by 21.88% to -$18.1 million in 2023, then dropped by 13.68% to -$20.6 million in 2024, then grew by 28.88% to -$14.6 million in 2025.
  • Business Quant data shows EBT for BRNS at -$14.6 million in Q3 2025, -$21.2 million in Q2 2025, and -$19.7 million in Q1 2025.